Stifel Nicolaus analyst James Orsborne maintained a Hold rating on Shield Therapeutics (STX – Research Report) yesterday and set a price target of p3.50.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
James Orsborne has given his Hold rating due to a combination of factors impacting Shield Therapeutics. The company’s revenue growth is notably driven by an increase in the net sales price (NSP) of Accrufer, which has mitigated the decrease in prescription volumes. Despite this positive development, the slowdown in prescription growth presents a concern, particularly given the significant growth seen in previous quarters.
Furthermore, while the company’s current cash position and additional funding provide a pathway to potential profitability, the timing of achieving cash flow positivity remains uncertain and could extend beyond 2025. This uncertainty, coupled with the need for continued strong growth in Accrufer prescriptions, underpins the cautious stance reflected in the Hold rating. The company is expected to update its forecasts as more data becomes available, which could influence future assessments of its financial outlook.
According to TipRanks, Orsborne is ranked #8764 out of 9356 analysts.